secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-311251
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio reports Phase 1b data: ABI-1179 98% HSV-2 shedding reduction, ABI-5366 monthly 76%
--------------------------------------------------------------------------------

- ABI-1179 50 mg weekly: 98% HSV-2 shedding reduction (p<0.01), exceeds 80-85% target; 91% lesion reduction (p<0.01).
- ABI-1179: >99% reduction in high viral load shedding, a transmission surrogate.
- ABI-5366 monthly dose: 76% HSV-2 shedding reduction (p<0.01), 88% lesion reduction (p=0.01), 81% high viral load reduction.
- ABI-5366 weekly 350 mg confirmed: 94% shedding, 97% lesion reduction vs placebo.
- Both candidates well-tolerated; Phase 2 planning for ABI-1179 and ABI-5366 weekly; monthly optimization ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312525311251/0001193125-25-311251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312525311251/asmb-20251208.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-311251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer